SLU‑PP‑332 is a synthetic small‑molecule research compound classified as a potent pan‑agonist of estrogen‑related receptors (ERRα, ERRβ, and ERRγ). It is studied for its potential role in regulating metabolic pathways and cellular energy homeostasis.

SLU‑PP‑332 works by binding to ERR receptors — nuclear transcription factors involved in the control of mitochondrial biogenesis, oxidative phosphorylation, and lipid metabolism. Activation of these receptors enhances expression of genes associated with mitochondrial function, fatty acid oxidation, and aerobic energy pathways, which in preclinical models mimics some molecular effects of endurance exercise.

It is commonly researched for its possible effects on improving mitochondrial efficiency, shifting fuel utilization toward oxidative metabolism, supporting metabolic flexibility, and exploring mechanisms related to metabolic syndrome, endurance adaptations, and energy regulation in laboratory settings.